 Verastem Oncology Inc NASDAQ: VSTM stock is trading higher after updated data from the ongoing Phase 12 FRAME study. The investigator-sponsored study is investigating VS-6766, Verastems RAFMEK inhibitor, in combination with defactinib, its FAK inhibitor, in patients with low-grade serous ovarian cancer LGSOC. 